Pathology Laboratory Testing at the Crossroads: Will Payers Deeply Discount Prices for Genetic Tests, or Will Value-Based Pricing Prevail?
Big changes in how these lab test claims are handled are just 11 weeks away, and most clinical laboratories are not up to speed on this issue
Note: Dark Daily offers this opinion and commentary by Editor Robert L. Michel
Big changes are coming in how payers handle code stacked claims for genetic tests and molecular diagnostic assays! However, few pathologists and clinical laboratory administrators understand why the collective efforts of payers to control utilization and reimbursement of these types of lab tests have the potential to undermine the financial stability of their medical laboratories and anatomic pathology groups.
The year 2012 is about to arrive and, when it does, it will bring the clinical laboratory testing industry to an important crossroads. Payers—both government and private—are ready to take decisive action to rein in an area of genetic and molecular testing that they consider to be on verge of spiraling out of their control.
(more…)
